Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17789030 | 0.73 | ERCC1 (0.34) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL17789017 | 0.70 | ERCC1 (0.34) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL17789014 | 0.70 | TSHR (0.37) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL17789029 | 0.69 | TSHR (0.35) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL17789049 | 0.69 | ERCC1 (0.33) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL17792494 | 0.67 | TP53 (0.33) | HSD17B10TP53MTNR1AMTNR1B | |
| SCHEMBL17789067 | 0.67 | ERCC1 (0.33) | KDM4EHSD17B10TSHRALDH1A1MAPT | |
| SCHEMBL17792537 | 0.65 | EZH2 (0.35) | KDM4EHSD17B10ALDH1A1MAPTALOX15 | |
| SCHEMBL17789018 | 0.65 | ERCC1 (0.36) | KDM4EHSD17B10TSHRALDH1A1TP53 | |
| SCHEMBL22674300 | 0.65 | EZH2 (0.50) | KDM4EHSD17B10TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20180065954-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2018-03-08 | — | — | US | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-08-03 | — | — | US | disclosed |
| US-9624205-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624205-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152604-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | KDM4E 1368/4885HSD17B10 393/4885TSHR 4392/4885 |
| US-20180065954-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS | KDM4E 1368/4885HSD17B10 393/4885TSHR 4392/4885 |
| US-20170217941-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | KDM4E 860/4885HSD17B10 951/4885TSHR 4488/4885 |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | KDM4E 860/4885HSD17B10 951/4885TSHR 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.